These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 35130881)
1. Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes. Qiu Z; Ji J; Xu Y; Zhu Y; Gao C; Wang G; Li C; Zhang Y; Zhao J; Wang C; Wen X; Zhang Z; Li B; Zhang Z; Cai S; Li B; Jiang X BMC Med; 2022 Feb; 20(1):64. PubMed ID: 35130881 [TBL] [Abstract][Full Text] [Related]
2. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses. Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649 [TBL] [Abstract][Full Text] [Related]
3. Novel insights into molecular and immune subtypes of biliary tract cancers. Bramel ER; Sia D Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699 [TBL] [Abstract][Full Text] [Related]
4. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577 [TBL] [Abstract][Full Text] [Related]
5. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis. Frega G; Cossio FP; Banales JM; Cardinale V; Macias RIR; Braconi C; Lamarca A Cells; 2023 Aug; 12(16):. PubMed ID: 37626908 [TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies. Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854 [TBL] [Abstract][Full Text] [Related]
7. The present roles and future perspectives of Interleukin-6 in biliary tract cancer. Zhou M; Na R; Lai S; Guo Y; Shi J; Nie J; Zhang S; Wang Y; Zheng T Cytokine; 2023 Sep; 169():156271. PubMed ID: 37331095 [TBL] [Abstract][Full Text] [Related]
8. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005 [TBL] [Abstract][Full Text] [Related]
9. Mutational spectrum and precision oncology for biliary tract carcinoma. Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015 [No Abstract] [Full Text] [Related]
10. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342 [TBL] [Abstract][Full Text] [Related]
11. The epidemiological trends of biliary tract cancers in the United States of America. Jiang Y; Jiang L; Li F; Li Q; Yuan S; Huang S; Fu Y; Yan X; Chen J; Li H; Li S; Liu J BMC Gastroenterol; 2022 Dec; 22(1):546. PubMed ID: 36581813 [TBL] [Abstract][Full Text] [Related]
12. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Tran Cao HS; Zhang Q; Sada YH; Chai C; Curley SA; Massarweh NN Cancer; 2018 Jan; 124(1):74-83. PubMed ID: 28841223 [TBL] [Abstract][Full Text] [Related]
13. Surgical Resection Alone is Associated With Higher Long-Term Survival Than Multiagent Chemotherapy Alone for Patients With Localized Biliary Tract Cancers. Elshami M; Ammori JB; Hardacre JM; Selfridge JE; Bajor D; Mohamed A; Chakrabarti S; Mahipal A; Winter JM; Ocuin LM J Surg Res; 2024 Mar; 295():705-716. PubMed ID: 38141457 [TBL] [Abstract][Full Text] [Related]
14. Genomics driven precision oncology in advanced biliary tract cancer improves survival. Kumar-Sinha C; Vats P; Tran N; Robinson DR; Gunchick V; Wu YM; Cao X; Ning Y; Wang R; Rabban E; Bell J; Shankar S; Mannan R; Zhang Y; Zalupski MM; Chinnaiyan AM; Sahai V Neoplasia; 2023 Aug; 42():100910. PubMed ID: 37267699 [TBL] [Abstract][Full Text] [Related]
15. The state of therapy modalities in clinic for biliary tract cancer. Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice. Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050 [TBL] [Abstract][Full Text] [Related]
18. Advances in Targeted Immunotherapy for Hepatobiliary Cancers. Ruff SM; Shannon AH; Pawlik TM Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078 [TBL] [Abstract][Full Text] [Related]
20. [Biliary tract cancers : Molecular characterization and identification of novel prognostic markers]. Goeppert B Pathologe; 2017 Nov; 38(Suppl 2):192-197. PubMed ID: 29063951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]